IBS vs IBD
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Here's a thorough comparison:
IBS vs IBD
These two conditions are frequently confused because they share overlapping symptoms, but they are fundamentally different in nature, pathology, and management.
The Core Distinction
| IBS | IBD | |
|---|---|---|
| Nature | Functional disorder (no structural/inflammatory damage) | Organic inflammatory disease (true tissue destruction) |
| Inflammation | None on biopsy or imaging | Chronic, relapsing mucosal/transmural inflammation |
| Cancer risk | Not increased | Significantly increased after 8–10 years of colonic disease |
| Systemic illness | No | Yes — fever, weight loss, anemia, growth delay |
| Biomarkers | Normal | Elevated CRP, ESR, fecal calprotectin, anemia |
IBS — Irritable Bowel Syndrome
Definition: A chronic functional bowel disorder characterized by recurrent abdominal pain associated with alterations in stool form and/or frequency (diarrhea, constipation, or both), without identifiable structural or biochemical abnormality. — Goldman-Cecil Medicine
Subtypes (Rome IV)
- IBS-D — diarrhea predominant (~35–40%)
- IBS-C — constipation predominant (~25%)
- IBS-M — mixed bowel habits (~35–40%)
- IBS-U — unclassified (<5%)
Subtypes can transition in the same patient over time.
Epidemiology
- Worldwide prevalence ~4.1% (Rome IV criteria)
- More common in women (5.2%) than men (2.9%)
- Incidence ~38 per 10,000 person-years
- Up to 50% of sufferers never seek care — Goldman-Cecil Medicine
Pathophysiology
IBS results from dysregulation of gut-brain interactions, leading to:
- Altered intestinal motility
- Visceral hypersensitivity
- Abnormal autonomic nervous system function
- Altered stress responsiveness
- Mucosal immune dysfunction
- Gut microbiota changes
- Abnormal CNS modulation of viscerosensory input
Risk factors include genetic predisposition, adverse childhood experiences, prior infectious gastroenteritis (post-infectious IBS), food triggers, and psychological stress. — Goldman-Cecil Medicine
Diagnosis
- Clinical diagnosis based on Rome IV criteria
- No definitive biomarker
- Labs and imaging are normal — used to exclude organic disease
- Key "alarm features" that should prompt workup for IBD: blood in stool, nocturnal symptoms, unintentional weight loss, fever, family history of IBD/colorectal cancer, onset after age 50
Treatment
IBS management is multimodal:
- Dietary: low-FODMAP diet, fiber modification
- Pharmacological:
- IBS-C: lubiprostone (chloride channel activator), linaclotide
- IBS-D: alosetron (5-HT₃ antagonist; approved for severe cases in women), antidiarrheals, rifaximin
- Anticholinergics/antispasmodics for pain
- Behavioral: CBT, gut-directed hypnotherapy, stress reduction — Katzung's Basic & Clinical Pharmacology; Goldman-Cecil Medicine
IBD — Inflammatory Bowel Disease
Definition: An umbrella term for Crohn disease (CD) and ulcerative colitis (UC) — chronic, relapsing inflammatory diseases of the GI tract. — Robbins & Kumar Basic Pathology
Pathophysiology
IBD develops from a dysregulated immune response to normal intestinal flora in a genetically susceptible host. It is now understood as a complex mucosal barrier disorder rather than classic autoimmune disease. Key mechanisms:
- Loss of normal tolerance to intestinal bacteria
- In UC: thinned mucosal layer → bacterial contamination
- In CD: defective mucosal layer → transmural bacterial invasion
- NOD2 and PTPN22 gene variants increase CD risk specifically; most other polymorphisms affect both CD and UC — ROSEN's Emergency Medicine; Robbins Cotran & Kumar
Crohn Disease vs Ulcerative Colitis
| Feature | Crohn Disease | Ulcerative Colitis |
|---|---|---|
| Location | Any part of GI tract; most common: terminal ileum + proximal colon | Colon and rectum only; always involves rectum |
| Inflammation depth | Transmural (full thickness) | Superficial (mucosal only) |
| Pattern | Skip lesions | Continuous, uninterrupted |
| Granulomas | Noncaseating granulomas common | Absent |
| Rectal involvement | Variable | Always |
| Extraintestinal | Arthritis, aphthous stomatitis, uveitis, erythema nodosum, ankylosing spondyloarthropathy | Inflammatory arthropathies, primary sclerosing cholangitis (PSC) |
| Diagnosis markers | ASCA (anti-Saccharomyces cerevisiae antibodies), elevated fecal calprotectin | P-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies), elevated fecal calprotectin |
| Surgery | Often needed; not curative — 50% require surgery within 10 years, 80% within 20 | Colectomy can be curative |
| Cancer risk | Increased (colonic disease) | Increased after 8–10 years |
— ROSEN's Emergency Medicine; Robbins & Kumar
Clinical Presentation
- Abdominal pain, bloody diarrhea, tenesmus, weight loss
- CD specifically: nocturnal diarrhea, fever, fatigue, perianal disease (fissures, fistulas, abscesses)
- Onset typically before age 30
- Pediatric clues: growth delay, pubertal delay, rectal bleeding, perianal skin tags
Complications
- Common: fistulae, strictures, abscesses
- Life-threatening: toxic megacolon, fulminant colitis, intestinal perforation
Toxic megacolon — colonic dilation from transmural inflammation causing muscle paralysis; hallmark is colonic dilation + systemic toxicity (fever, >10 stools/day, continuous bleeding). Seen most commonly with UC.
Extraintestinal Manifestations (~1/3 of IBD patients)
- Skin: erythema nodosum, pyoderma gangrenosum
- Eyes: episcleritis, scleritis, uveitis
- Joints: arthritis, sacroiliitis
- Liver: PSC (especially in UC)
- Vascular: thromboembolic events (often underdiagnosed)
Diagnosis
- Endoscopy with biopsy (gold standard)
- Elevated fecal calprotectin (key: distinguishes IBD from IBS)
- Stool lactoferrin, ASCA, P-ANCA serology
- Lab findings: anemia, elevated CRP/ESR, hypoalbuminemia
Fecal calprotectin is particularly useful for differentiating IBD from IBS — Tietz Textbook of Laboratory Medicine
Treatment
| Drug Class | CD | UC |
|---|---|---|
| Aminosalicylates (mesalamine, sulfasalazine) | Less effective | First-line (oral or rectal) |
| Corticosteroids (budesonide, systemic) | First-line for active flares | Reserved for when aminosalicylates fail |
| Immunomodulators (mercaptopurine, azathioprine) | Moderate-severe disease | Moderate-severe disease |
| Biologics (anti-TNF: infliximab, adalimumab) | Refractory or severe | Refractory or severe |
| Surgery | Stricture/fistula complications; not curative | Colectomy is curative |
— Katzung's Basic & Clinical Pharmacology; ROSEN's Emergency Medicine
Key Differentiating Features at a Glance
| Feature | IBS | IBD |
|---|---|---|
| Blood in stool | No | Yes (especially UC) |
| Nocturnal symptoms | Rare | Common |
| Weight loss / fever | No | Yes |
| Normal colonoscopy/biopsy | Yes | No |
| Fecal calprotectin | Normal | Elevated |
| CRP / ESR | Normal | Elevated |
| Anemia | No | Common |
| Perianal disease | No | Yes (CD) |
| Treatment goal | Symptom control | Induce + maintain remission, prevent complications |
| Curable? | No (managed) | UC: yes (colectomy); CD: no |
Sources: Goldman-Cecil Medicine; ROSEN's Emergency Medicine; Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease; Katzung's Basic & Clinical Pharmacology; Tietz Textbook of Laboratory Medicine
This is a shared conversation. Sign in to Orris to start your own chat.